- Home
- MSB vs ABEO Comparison
MSB vs ABEO Comparison
Compare MSB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- ABEO
- Stock Information
- Founded
- MSB 1961
- ABEO 1974
- Country
- MSB United States
- ABEO United States
- Employees
- MSB N/A
- ABEO N/A
- Industry
- MSB Metal Mining
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- ABEO Health Care
- Exchange
- MSB Nasdaq
- ABEO Nasdaq
- Market Cap
- MSB 318.2M
- ABEO 256.9M
- IPO Year
- MSB N/A
- ABEO 1980
- Fundamental
- Price
- MSB $25.08
- ABEO $5.69
- Analyst Decision
- MSB
- ABEO Strong Buy
- Analyst Count
- MSB 0
- ABEO 6
- Target Price
- MSB N/A
- ABEO $18.00
- AVG Volume (30 Days)
- MSB 35.2K
- ABEO 1.1M
- Earning Date
- MSB 01-01-0001
- ABEO 08-11-2025
- Dividend Yield
- MSB 27.37%
- ABEO N/A
- EPS Growth
- MSB 335.65
- ABEO N/A
- EPS
- MSB 7.12
- ABEO N/A
- Revenue
- MSB $25,894,592.00
- ABEO N/A
- Revenue This Year
- MSB N/A
- ABEO N/A
- Revenue Next Year
- MSB N/A
- ABEO $323.51
- P/E Ratio
- MSB $3.47
- ABEO N/A
- Revenue Growth
- MSB N/A
- ABEO N/A
- 52 Week Low
- MSB $15.93
- ABEO $3.93
- 52 Week High
- MSB $37.00
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- MSB 52.13
- ABEO 47.54
- Support Level
- MSB $24.00
- ABEO $5.68
- Resistance Level
- MSB $25.48
- ABEO $5.93
- Average True Range (ATR)
- MSB 1.01
- ABEO 0.26
- MACD
- MSB 0.18
- ABEO -0.01
- Stochastic Oscillator
- MSB 81.09
- ABEO 56.25
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.